T1	p 27 123	at high risk for neutropenic complications during chemotherapy for metastatic breast cancer with
T2	p 401 449	patients with metastatic breast cancer ( MBC ) .
T3	p 636 643	n = 509
T4	i 124 172	doxorubicin or pegylated liposomal doxorubicin :
T5	i 314 326	chemotherapy
T6	i 332 354	doxorubicin ( DOX ) or
T7	i 357 396	pegylated liposomal formulation ( PLD )
T8	i 524 532	DOX ( 60
T9	i 550 576	3 weeks ) or PLD ( 50 mg/m
T10	i 597 598	)
T11	i 618 625	therapy
T12	i 648 655	O'Brien
T13	i 1378 1390	chemotherapy
T14	i 1393 1396	DOX
T15	i 1404 1407	PLD
T16	i 1796 1805	therapies
T17	i 1813 1859	granulocyte colony stimulating factor or PLD )
T18	o 648 655	O'Brien
T19	o 823 857	febrile neutropenia or neutropenia
T20	o 1259 1277	performance status
T21	o 1280 1305	absolute neutrophil count